SSG
MRNA icon

Summit Securities Group’s Moderna MRNA Stock Holding History

Summit Securities Group’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.74K Sell
82
-1,544
-95% -$79.9K ﹤0.01% 954
2026
Q1 		$82.6K Buy
1,626
+1,109
+215% +$51.7K 0.01% 311
2025
Q4 		$15.2K Sell
517
-79
-13% -$2.15K ﹤0.01% 847
2025
Q3 		$15.4K Buy
596
+367
+160% +$10.2K ﹤0.01% 825
2025
Q2 		$6.32K Buy
+229
New +$6.03K ﹤0.01% 955
2024
Q3 		– Sell
-51
Closed -$6K – 756
2024
Q2 		$6K Buy
+51
New +$6.45K ﹤0.01% 481
2024
Q1 		– Sell
-31
Closed -$3K – 746
2023
Q4 		$3K Sell
31
-1,012
-97% -$85.1K ﹤0.01% 605
2023
Q3 		$108K Buy
1,043
+482
+86% +$53.8K 0.01% 213
2023
Q2 		$68K Buy
+561
New +$74.8K 0.01% 346
2022
Q4 		– Sell
-1,456
Closed -$172K – 1289
2022
Q3 		$172K Buy
+1,456
New +$221K 0.01% 441
2022
Q2 		– Sell
-1,801
Closed -$310K – 1128
2022
Q1 		$310K Buy
+1,801
New +$303K 0.03% 303
2021
Q1 		– Sell
-12,200
Closed -$1.27M – 704
2020
Q4 		$1.27M Buy
+12,200
New +$1.23M 0.11% 205

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Summit Securities Group's MRNA Position: Q2 2026 in Review

Summit Securities Group reduced its Moderna (MRNA) stake by 95% in Q2 2026, selling an estimated $79.9K and leaving 82 shares worth $5.74K. The position accounts for ﹤0.01% of the portfolio, ranked #954.

Summit Securities Group first reported a position in MRNA in Q4 2020 and has held it in 12 quarters since. The position peaked at $1.27M in Q4 2020. 775 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Summit Securities Group held 82 shares of Moderna worth $5.74K as of Q2 2026.
  • Summit Securities Group sold 1,544 Moderna shares in Q2 2026, an estimated $79.9K.
  • Moderna made up ﹤0.01% of Summit Securities Group's portfolio in Q2 2026, its #954 holding.
  • Summit Securities Group first reported a position in Moderna in Q4 2020 and has held it in 12 quarters since.
  • Summit Securities Group's Moderna position peaked at $1.27M in Q4 2020.
  • 775 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Summit Securities Group's 13F filing for Q2 2026, filed 3 Aug 2026.